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Abstract
Background: Gulf War Illness (GWI) is a clinically heterogeneous chronic condition that affects many veterans of
the 1990–1991 Persian Gulf War. One of the most prevalent and debilitating symptoms of GWI is abnormal fatigue.
The mechanisms underlying GWI generally, and fatigue symptoms specifically, have yet to be conclusively identified,
although immune system abnormalities are suspected to be involved. The first goal of this immune monitoring study
was to determine if GWI is associated with higher absolute levels and daily variability of pro-inflammatory immune
factors. The second goal was to explore the relationship between day-to-day immune marker fluctuations and daily
self-reported fatigue severity.
Methods: We recruited veterans with GWI and healthy veteran control (HV) participants to provide self-reported
fatigue severity data and blood samples, over 25 consecutive days. We profiled inflammatory processes by using a
longitudinal, daily immune-monitoring approach. For each day, serum cytokine and chemokine concentrations were
determined using multiplex assays.
Results: Seven veterans with GWI and eight healthy veteran control (HV) participants completed the study protocol.
We found that GWI was associated with higher variability in the expression of eotaxin-1 (p < 0.001). For GWI
participants, higher fatigue severity days were associated with greater IL-1β (p = 0.008) and IL-15 (p < 0.001).
Conclusions: Our findings provide preliminary evidence that the immune system is involved in the pathophysiology
of GWI. Longitudinal immune profiling approaches may be helpful in discovering targets for novel therapies in
conditions such as GWI.
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Background
Gulf War Illness (GWI) is a chronic condition that
affects military veterans of the 1990 – 1991 Persian Gulf
War. The clinical manifestation of GWI is heteroge-
neous; symptoms can include fatigue, cognitive prob-
lems, widespread pain, gastrointestinal issues, respiratory
difficulties, and dermatological complaints [1, 2].
The mechanisms underlying GWI have not been prop-
erly resolved, although abnormal immune function has
been proposed to play a role. One etiological hypothesis
suggests that immune challenges due to various
environmental exposures, possibly exacerbated by condi-
tions of battle stress, may have resulted in chronic dys-
regulation of the immune system [3–7]. Unfortunately,
while a specific immunological signature for GWI holds
great diagnostic appeal, the question whether GWI is as-
sociated with immune dysregulation has not been conclu-
sively answered. Some groups have suggested that the
underlying immune dysregulation involves a polarization
towards either the T-helper 2 (Th2) [8] or Th1 [9, 10] dir-
ection. It has also been suggested that interleukin (IL)-1β
is involved [11] as it is an important driver of sickness
responses [12] that can resemble the symptoms of GWI.
However this is challenged by at least one study, which
reported that concentrations of IL-1β in plasma and
following ex vivo stimulation of peripheral blood
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mononuclear cells were no different in GWI than in a
veteran control group [13]. Results from whole blood
analyses have suggested normal lymphocyte function in
GWI [14], while others have reported that GWI may be
associated with changes in the populations and function
of B and T immune cells [15–19]. Routine clinical and
rheumatological blood tests have generally been shown to
be normal [18, 20], including tests for autoimmune condi-
tions, such as the antinuclear antibody (ANA) [21].
Although activated immune processes may underlie
the symptoms of GWI, research results to date remain
inconclusive. One possible issue with present data is
that, with a few notable exceptions [15–19], most past
attempts at exploring immune pathology in GWI have
involved cross-sectional, patient-versus-control designs.
Such approaches may be insensitive to pathophysio-
logical inflammation processes if significant day-to-day
fluctuations are common in the patient group. Factors
that drive disease processes may also be missed if those
factors operate in clinically “normal” ranges, but still
drive symptoms because of sensitized downstream tar-
gets. For those reasons, experimental exercise-based
stimulation paradigms have been employed to assess
immune system function [16]. We have also proposed a
daily immune monitoring approach, which allows us to
examine immune responses to typical daily stimuli and
experiences [22]. Daily sampling of immune variables
also allows more accurate individual means to be com-
puted, variability across time to be calculated, and asso-
ciations between analyte fluctuations and symptom
severity to be explored. Longitudinal immune monitor-
ing designs therefore allow the immune system to be
examined in ways not possible with cross-sectional
designs.
The overall goal of this preliminary analysis was to test
whether GWI is associated with either abnormal concen-
trations or abnormal fluctuations in pro-inflammatory
and anti-inflammatory immune markers. In this longitu-
dinal study, we examined blood sera collected over 25
consecutive days from veterans who met the Kansas GWI
case definition criteria [23] and from healthy veterans of
the Gulf War (HV). Three hypotheses were generated for
the analyses. First, that serum pro-inflammatory cytokines
would be higher in GWI than in HV. Second, that
cytokine fluctuations would be greater in GWI than
in HV. Third, that daily self-reported fatigue in GWI
individuals would covary with the concentrations of
pro-inflammatory cytokines.s. We focused on fatigue
because it has been identified as one of the most
significant and common problems in GWI [23–26].
Although involving few participants, this study uti-
lized intensive longitudinal data to explore unique
questions about the role of systemic inflammation in
the symptoms of GWI.
Results
Participants
We included seven GWI and eight HV participants in
this study. Five additional GWI participants were re-
cruited but subsequently excluded from the study: three
due to exclusionary blood test results, including a posi-
tive and high ANA, a high thyroid-stimulating hormone
(TSH) level indicating a thyroid disorder, and a high
erythrocyte sedimentation rate (ESR) and C-reactive
protein (CRP) level indicating a possible autoimmune
disorder; one due to a HADS depression score above the
study cut-off; and one because he did not experience any
symptoms during the study period, which was highly
atypical of his usual symptomatology. Of the 15 included
participants, one GWI participant withdrew after 19
consecutive blood draws, however we resolved that he
had contributed enough data to be included in the ana-
lyses. All other participants had blood draws collected as
described in the protocol. The participant demographics
and relevant baseline measures are shown in Table 1.
Main results
First, the between-group (GWI versus HV) differences in
serum cytokine concentrations were assessed (Table 2;
column 7).We found no significant main differences in
the levels of serum-expressed cytokines in the GWI and
HV groups.
Second, we contrasted the magnitude of day-to-day
fluctuations in serum cytokine concentrations between
the GWI and HV groups (Table 2; column 6). Compared
to HV, GWI participants had higher variability in the ex-
pression of eotaxin-1 (coefficient of variation (CV) =
23.89 ± 3.99 % vs. 15.27 ± 1.78 %; p < 0.001). No other
analytes were more variable in the HV group than in the
GWI group.
Finally, in the GWI group only, we tested for associa-
tions between analytes and daily fatigue severity (Table
2; column 8). Fatigue severity was positively associated
with IL-1β (F = 7.238, p = 0.008) and IL-15 (F = 21.951,
p < 0.001).
In all analyses, significance was determined using a false
discovery rate (FDR) corrected threshold of p = 0.0098.
Results of all analyses are shown in Table 2. Because in
the GWI cohort, the levels of IL-15 were most strongly
correlated with day-to-day changes in fatigue severity, we
have also presented time-series plots that show the rela-
tionship between IL-15 and fatigue for each individual
participant (Fig. 1).
Discussion
The goal of this study was to explore inflammatory dys-
regulation as a potential component of the pathophysi-
ology of GWI, by using a daily immune monitoring
approach. We explored differences in the absolute
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1 HV 47 Caucasian 9 neg. 0 1 1 0 ± 0 6.3 242 <0.2 0 neg. 1.11 neg.
2 HV 50 Asian 1 neg. 0 0 1 0 ± 0 4.7 219 <0.2 1 neg. 1.24 neg.
3 HV 42 Caucasian 15 neg. 1 1 3 17 ± 6 5.1 218 <0.2 0 neg. 0.86 neg.
4 HV 41 Caucasian 6 neg. 0 6 1 0 ± 0 7.3 212 <0.2 4 neg. 1.04 neg.
5 HV 57 Caucasian 0 neg. 0 2 0 2 ± 3 6.3 239 0.8 30 neg. 0.96 neg.
6 HV 54 Caucasian 1 neg. 3 14 11 65 ± 25 7.0 234 <0.2 5 neg. 1.83 neg.
7 HV 44 Caucasian 1 neg. 2 5 4 0 ± 0 9.4 189 0.5 5 neg. 2.42 neg.
8 HV 48 Latino 0 neg. 0 3 1 5 ± 16 7.9 332 0.6 2 neg. 0.96 neg.
9 GWI 41 Caucasian 42* neg. 6 8 7 50 ± 14 10.1 262 0.2 1 1:80 1.27 neg.
10 GWI 42 Caucasian 1 neg. 2 11 10 25 ± 15 6.6 212 <0.2 2 neg. 1.98 neg.
11 GWI 44 Pacific
Islander
1* neg. 2 6 7 65 ± 12 12.3 284 1.0 1 neg. 2.22 neg.
12 GWI 48 Caucasian 0 neg. 5 8 3 37 ± 15 7.4 256 <0.2 2 neg. 1.49 neg.
13 GWI 48 Asian 0 neg. 2 11 6 11 ± 11 4.4 188 <0.2 9 neg. 1.90 neg.
14 GWI 47 Caucasian 7 neg. 2 5 1 21 ± 16 5.8 191 <0.2 2 neg. 1.08 neg.
15 GWI 43 Caucasian 6 neg. 3 9 4 24 ± 19 5.3 278 <0.2 2 neg. 0.63 neg.
Except for fatigue, all data shown were obtained during each participant’s screening session. Fatigue means and standard deviations were calculated for each participant from the self-report scores provided during the
immune-monitoring phase. HADS = Hospital Anxiety and Depression Score. Blood test results include white blood cell count (WBC), platelets, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), antinuclear
antibody test (ANA), thyroid stimulating hormone (TSH), and rheumatoid factor test (RHF). Neg. = negative. *Participant 9 currently diagnosed with alcohol addiction; participant 11 recovered from alcohol addiction.
There was no significant difference in alcohol intake between the healthy (median = 1; IQR = 6) and the GWI (median = 1; IQR = 7) groups (U = 27.0, p = 0.955). There was a significant difference in HADS-Anxiety













concentrations and fluctuations of cytokines in GWI in-
dividuals and healthy Gulf War veteran controls. We
also explored the relationship between daily cytokine
fluctuations and changes in fatigue severity in individuals
with GWI. We found that, compared to HV, GWI was
associated with higher variability of eotaxin-1. For GWI
participants, higher fatigue days were associated with
greater concentrations of IL-1β and IL-15. As shown in
Fig. 1, we observed that the relationships between IL-15
and fatigue over time vary considerably across individ-
uals, however overall moderate positive relationships be-
tween the two variables can be seen. Combined, our
results appear to support the hypothesis that the patho-
physiology of GWI involves immune dysregulation.
Main study findings
The cytokine IL-1β is a classic pro-inflammatory cyto-
kine that is inhibited by the release of its receptor antag-
onist IL-1Ra [27]. That IL-1Ra expression was not found
to be different in GWI or to be associated with fatigue
suggests that a pro-inflammatory increased IL-1β/IL-1Ra
ratio may be associated with fatigue. IL-1β is an important
driver of the classic sickness response, which includes pro-
found fatigue in both animals and humans [28]. Previous
reports have been published of higher circulating levels of
IL-1 in patients with myalgic encephalomyelitis/chronic
fatigue syndrome [29–31] and that, in some medical con-
ditions, the inhibition of IL-1 is associated with decreased
fatigue [32, 33]. While we did not find increased concen-
trations of IL-1β in blood obtained from people with
GWI, in agreement with prior work in this condition [13],
we found that the levels of this cytokine were associated
with fatigue. This offers some support to an early theory
which suggested that IL-1β may play an important role in
the pathophysiology of GWI [11].
IL-15 is a more recently discovered pro-inflammatory
cytokine with angiogenic [34], anabolic muscle [35], T-
cell activating [36], and microglial activating [37] effects.
Prior work has shown that chronic fatigue syndrome
may be associated with reduced IL-15 and, in turn,
Table 2 Results of statistical tests comparing cytokine expression in the GWI and HV groups
Immune
biomarker














BDNF 23.36 (8.84) 29.78 (22.28) 23.97 (6.79) 16.86 (6.24) t(13) = −1.578, p = 0.138 χ2 = 0.068, p = 0.794 F = 0.911, p = 0.341
Eotaxin-1 168.94 (66.21) 23.89 (3.99) 227.17 (129.9) 15.27 (1.78) t(11) = −5.173, p ≤ 0.001 χ2 = 3.221, p = 0.073 F = 3.467, p = 0.065
Factor VII 391.89 (124.38) 9.71 (4.75) 407.54 (54.29) 7.74 (1.63) t(13) = −1.104, p = 0.290 χ2 = 0.180, p = 0.671 F = 0.849, p = 0.358
ICAM-1 118.89 (32.35) 10.6 (3.58) 125.21 (34.4) 9.59 (2.52) t(13) = −0.639, p = 0.534 χ2 = 0.429, p = 0.512 F = 0.035, p = 0.852
IL-1β 4.49 (0.7) 15.61 (3.24) 3.84 (0.39) 10.49 (3.09) t(12) = −3.011, p = 0.011 χ2 = 5.204, p = 0.023 F = 7.238, p = 0.008
IL-1Ra 579.28 (184.39) 25.68 (7.62) 636.16 (106.9) 21.87 (3.75) t(13) = −1.257, p = 0.231 χ2 = 0.161, p = 0.688 F = 2.140, p = 0.145
IL-8 7.06 (1.42) 27.42 (15.1) 7.54 (3.88) 28.21 (13.9) t(13) = 0.106, p = 0.917 χ2 = 0.483, p = 0.487 F = 5.046, p = 0.026
IL-10 6.09 (0.57) 17.23 (8.15) 5.69 (0.26) 16.07 (7.39) t(8) = −0.235, p = 0.820 χ2 = 2.890, p = 0.089 F = 0.837, p = 0.364
IL-12p40 0.39 (0.1) 19.03 (2.34) 0.46 (0.07) 15.98 (3.1) t(13) = −2.126, p = 0.053 χ2 = 1.845, p = 0.174 F = 3.418, p = 0.066
IL-15 0.76 (0.1) 15.6 (2.77) 0.73 (0.1) 14.49 (3.5) t(11) = −0.600, p = 0.561 χ2 = 1.366, p = 0.242 F = 21.951, p ≤ 0.001
IL-17 4.02 (0.27) 21.34 (12.13) 3.78 (0.19) 5.51 (9.55) t(4) = −1.776, p = 0.150 χ2 = 2.379, p = 0.123 F = 0.391, p = 0.536
IL-18 287.44 (83.16) 12.79 (3.72) 243.66 (102.56) 10.38 (3.8) t(13) = −1.236, p = 0.238 χ2 = 0.670, p = 0.413 F = 0.973, p = 0.325
IL-23 1.93 (0.11) 13.58 (3.76) 1.9 (0.13) 9.29 (2.84) t(10) = −2.259, p = 0.047 χ2 = 1.280, p = 0.258 F = 1.320, p = 0.255
MIP-1α 35.24 (2.24) 7.26 (3.96) 38.87 (6.28) 7.94 (4.18) t(6) = 0.237, p = 0.821 χ2 = 0.243, p = 0.622 F = 0.367, p = 0.547
MIP-1β 246.95 (82.29) 21.41 (7.05) 342.66 (125.03) 13.58 (4.42) t(13) = −2.536, p = 0.030 χ2 = 3.121, p = 0.077 F = 4.451, p = 0.036
MMP-3 12.32 (5.2) 18.25 (7.12) 14.91 (5.81) 17.19 (8.39) t(13) = −0.262, p = 0.797 χ2 = 0.745, p = 0.388 F = 1.140, p = 0.287
MMP-9 58.31 (15.98) 21.9 (8) 65.44 (28.67) 18.87 (3.42) t(13) = −0.977, p = 0.346 χ2 = 0.428, p = 0.513 F = 0.865, p = 0.354
MCP-1 295.95 (173.89) 21.75 (7.38) 419.04 (167.77) 18.07 (8.38) t(13) = −0.897, p = 0.386 χ2 = 2.704, p = 0.100 F = 1.142, p = 0.287
SCF 400.74 (98.01) 16.05 (3.18) 496.78 (80.29) 13.31 (2.31) t(13) = −1.925, p = 0.076 χ2 = 4.302, p = 0.038 F = 2.560, p = 0.111
VEGF 161.42 (82.29) 19.92 (9.36) 190.26 (86.36) 13.64 (4.62) t(13) = −1.684, p = 0.116 χ2 = 1.079, p = 0.299 F = 4.370, p = 0.038
Leptin 13.51 (6.25) 18.09 (4.4) 12.59 (10.22) 15.68 (3.47) t(13) = −1.182, p = 0.258 χ2 = 0.003, p = 0.958 F = 0.405, p = 0.525
For each analyte: columns 2–5 show the mean and standard deviation (sd) of the cytokine concentrations (conc.) and the day-to-day cytokine fluctuations
(presented as the coefficient of variation or CV); column 6 shows the results of group comparison tests of the CVs between GWI and HV; column 7 shows the
results of group comparisons of serum concentrations between GWI and HV; the last column shows the results of tests for associations between cytokine and
symptom variability in GWI. Statistically significant results are bolded and underlined (at p=0.0098 which is α=0.05 adjusted for the expected false discovery rate
in 93 statistical tests).
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reduced natural killer cell activity [38]. A reduced IL-15
response to high-intensity exercise, but not at rest, has
also been shown in males with GWI [39]. In the present
study, we did not find any differences in the expression
of IL-15 between GWI and HV, but its concentration
was strongly and positively associated with fatigue. The
mechanism of this is not clear. However, based on prior
research that reported changes in CD8+ T-cell expres-
sion and function in GWI and chronic fatigue syndrome
[19, 40], the changes in IL-15 expression may suggest
that daily fatigue is associated with an altered immune
response to activity and other stressors. Because we did
not test immune cell populations, future work should
also consider testing T-cell populations in addition to
circulating cytokines to determine the mechanism of
action.
Finally, we found that GWI individuals also showed
abnormally high fluctuations in eotaxin-1 (CCL11).
Eotaxin-1 is a chemotactic cytokine whose role in al-
lergy has been well-defined. More recently, it has been
suggested that eotaxin-1 may impair cognitive function
through an inhibitory effect on neurogenesis [41].
However the role that this chemokine may play in
GWI is not clear.
While this study does not elucidate the specific
mechanisms through which these cytokines and fa-
tigue are related, our data suggest that this may take
place through a pro-inflammatory modulation of im-
mune function in response to day-to-day activity.
Since we did not find increased concentrations of IL-
1β and IL-15 in GWI, our data also suggest that GWI
is associated with a more labile immune system and
perhaps a change in sensitivity to the expression of
these cytokines. One possibility underlying these find-
ings is that the immune system of people with GWI
may be more reactive to daily stressors. This appears
consistent with the hyper-reactive immune responses
to exercise in people with GWI that were identified in
prior work [15, 17, 19].
Interestingly, the present results contrast our earlier
finding that the adipokine leptin is associated with
self-reported fatigue in many people with chronic fa-
tigue syndrome/myalgic encephalomyelitis [22]. First,
it is possible that while fatigue is a distinct symptom,
its underlying mechanisms may differ between people
and among the various medical conditions. Second, the
relationships between the immune modulators and fa-
tigue may be more complex than those tested in the
present study. We will aim to explore these possibil-
ities in future studies.
Study strengths and limitations
We highlight four limitations of this study. First, the par-
ticipant sample size was small. The potential loss of power
due to a small sample size was mitigated by the intensive
longitudinal format of the study, yielding significant power
through within-person repeated measures. The daily im-
mune monitoring approach provides a rich dataset that al-
lows unique questions to be asked of the immune system,
including the within-person relationships between clinical
and physiological variables. However we also suggest cau-
tion due to the unknown generalizability of our findings;
future validation in an independent sample will help in re-
solving this uncertainty.
The second potential limitation of this study is related
to the selection of fatigue as a dependent variable. Al-
though GWI is a heterogeneous condition, due to the
small sample size we avoided the testing of complex dis-
ease models and only focused our attention on fatigue
because of its importance in the condition. However, it
is possible that other relationships exist between inflam-
matory processes and other symptoms of GWI such as
pain or cognitive problems.
Our third concern lies in the finding that the GWI
group reported significantly more anxiety at baseline than
did the HV group. It is possible that anxiety may play a
role in GWI and that it may be a confounder of the pre-
sented relationships. We will investigate this possibility in
our future research with a larger cohort.
Finally, while we collected information about specific
exposure variables such as vaccination and environmental
toxins encountered during deployment, we did not control
for these variables in the analyses. We made this decision
because accurate records of these exposures are not avail-
able. However, we attempted to control for this methodo-
logically by using a control group that was composed of
Gulf War veterans who did not experience GWI.
Methodological considerations and recommendations
In this study, we used the relatively rare approach of col-
lecting blood samples daily in GWI individuals and con-
trols. While more demanding of time and resources, the
longitudinal approach has two main advantages. First,
serial longitudinal measurements are better than a single
cross-sectional snapshot at capturing the functional
immune profile of a participant. Second, because
(See figure on previous page.)
Fig. 1 z-scored 3-day-smoothed serum IL-15 concentration (thin line) plotted against z-scored 3-day-smoothed daily self-reported fatigue (thick line), by
participant. IL-15 concentration/fatigue severity are represented on the y-axis. Time is represented on the x-axis. IL-15 was selected for display as our statis-
tical tests suggested that it was most significantly associated with fatigue severity fluctuations. Two participants did not express IL-15 at concentrations that
were measurable
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longitudinal studies obtain a series of observations that
are taken over a representative period, they allow for the
testing of causal relationships. Rheumatological and
non-rheumatological inflammatory conditions are asso-
ciated with significant low and high frequency variability
in symptoms such as fatigue [42–45]. Frequent longitu-
dinal assessments can allow those fluctuations to be
described, and allow more complex relationships (such
as time-lagged) to be explored.
Conclusions
A limited understanding of the pathophysiology of GWI
has impeded the development of specific and effective ther-
apeutics. Importantly, the precise relationship between im-
mune function and GWI symptoms is not known. In this
study, we reported a potential relationship between GWI
and serum-concentrations of eotaxin-1. We also found a
temporal relationship between serum-concentrations of IL-
1β and IL-15 and symptoms of fatigue in GWI.
Methods
Participant recruitment and consent
Study procedures were conducted as approved by the
Institutional Review Board at Stanford University. All
participants provided written informed consent includ-
ing consent for publication of data. Participants were
recruited through radio advertisements broadcast in the
San Francisco Bay Area, advertisements on Craigslist,
online support groups, and advertisements at the Veterans
Affairs Palo Alto Health Care System.
Participant inclusion and exclusion criteria were ini-
tially determined following a phone pre-screening inter-
view. Males between the ages of 39 and 65 were
considered for this study. Potential participants were
excluded for current use of opioid medications, signifi-
cant psychological comorbidities, current involvement in
litigation or worker’s compensation claims, current use
of blood thinning medications, or current regular use of
any anti-inflammatory medication (such as aspirin, ibu-
profen, or naproxen) which may have confounded the
inflammatory data. Participants were also required to
provide 25 consecutive daily blood draws, either at
Stanford University or through a mobile phlebotomy
service (Health Exams Inc., Burlingame, CA).
Secondary screening was conducted in person at the
Stanford Adult and Pediatric Pain Laboratory. During
this appointment, detailed participant demographic and
medical history information were collected. Individuals
were admitted into one of two study groups, GWI or
HV. Participants included in the GWI group met the
Kansas Gulf War Illness case definition criteria [23]. In
brief, these criteria restrict the diagnosis to veterans who
were deployed to the Persian Gulf and subsequently re-
ported moderate to severe symptoms in three out of six
symptom categories: fatigue or sleep problems; pain
symptoms; neurologic, cognitive or mood symptoms;
gastrointestinal symptoms; respiratory symptoms; and
skin symptoms [23]. Participants in the HV group were
required to have been deployed during the Gulf War, to
be free of any current major medical diagnoses, and to
not report daily pain or fatigue at the time of the assess-
ment. Exclusionary criteria for all participants included a
depression subscale score of ≥16 on the Hospital Anxiety
and Depression Scale (HADS) [46], a score of ≥50 on the
Military Post Traumatic Stress Score [47], or current use
of opioid analgesics or anti-inflammatories. Individuals
were also excluded if screening blood tests showed abnor-
mal values of thyroid hormone, an ANA ratio >1:80,
erythrocyte sedimentation rate (ESR) >60 mm/h, positive
rheumatoid factor, C-reactive protein over 1.0 mg/L, or
clinically abnormal results of a complete blood count test
according to the testing laboratory’s reference ranges.
Study design
We used an observational longitudinal design to test the
role of immune function in GWI. The 42-day study
began with the screening session during which partici-
pants were provided with the data collection device and
instructed in its use. The study consisted of a two-week
baseline symptom reporting phase, followed by 25 con-
secutive days of symptom reporting and venous blood
draws, and ended with a three day follow-up phase dur-
ing which participants reported their daily symptoms.
Participants could miss up to 2 days consecutively under
special circumstances, in which case additional days
were added to the end so that 25 days total were
assessed.
Questionnaire data collection
Baseline questionnaires used for screening purposes in-
cluded the Kansas Gulf War Veterans Health Project
Questionnaire [23] and the Hospital Anxiety and
Depression Scale [46]. Daily GWI symptoms were scored
by the participants on 0–100 visual analog scales (VAS),
using commercial survey software (Dooblo SurveyToGo,
Kefar Sava, Israel) on an android-based device. Fatigue,
the primary dependent variable, was assessed by asking,
“How fatigued have you felt today?” The VAS was an-
chored on the left by “No fatigue at all” and on the right
by “Severe fatigue”. Similar 101-point VAS were used to
collect information about other symptoms in the GWI
diagnostic criteria, but were not analyzed in this study.
The daily self-report measures were completed by the
participants in the afternoon or evening.
Immune data collection
During the 25-day immune monitoring phase, blood was
collected by trained phlebotomists or research nurses at
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the Stanford Clinical and Translational Research Unit
(CTRU) or a mobile phlebotomy service (Health Exams
Inc). Venous blood was generally collected from the
cubital fossa using a 23-gauge butterfly needle into two
4 cc serum separating tubes. The venipuncture site was
rotated daily to minimize participant discomfort and to
maintain local vein integrity. Obtained blood samples
were coagulated at room temperature for 30 min, centri-
fuged at 350 g for 15 min, and the serum layer was then
aliquotted into vials for storage at −80 °C. Phlebotomy
visits were scheduled within a two-hour window for each
participant, to minimize the effect of diurnal variation
on cytokine concentrations [48, 49]. Blood pressure,
heart rate, and body temperature were also collected
during each visit to monitor for signs of emerging acute
illness.
Concentrations of cytokines and chemokines in
serum samples were determined by Myriad RBM, Inc.
using a standardized protocol. In short, Tecan EVO®
robots were used to combine an aliquot of each sample
with the capture microspheres and incubated for one
hour at room temperature. Multiplexed cocktails of
biotinylated reporter antibodies were then added robotic-
ally, thoroughly mixed, and incubated for an additional
hour at room temperature. Multiplexes were developed
using an excess of streptavidin-phycoerythrin solution
which was thoroughly mixed into each multiplex and
incubated for one hour at room temperature. The volume
of each multiplexed reaction was reduced by vacuum fil-
tration and the volume increased by dilution into matrix
buffer for analysis. Analysis was performed in a Luminex
instrument and the resulting data stream was interpreted
using proprietary PlateReader data analysis software.
Assays were run in high density multiplexed panels and
the least detectable dose (LDD) was determined as the
mean +3 standard deviations of 20 sample diluent read-
ings. An eight (n = 8) point standard curve was used to
obtain quantitative measurements for each sample. Stan-
dards and quality controls were run on each plate with a
replicate of each standard positioned in the first and last
column of the plate. Quality controls were run in dupli-
cate along different points of the curve to ensure both
accuracy and precision for each analyte. The analytes
included in the assays and their LDD were: Brain-Derived
Neurotrophic Factor (BDNF) [0.027 ng/mL], Eotaxin-1/
CCL11 [67 pg/mL], Factor VII [3.3 ng/mL], Granulocyte-
Macrophage Colony-Stimulating Factor (GM-CSF) [14 pg/
mL], Intercellular Adhesion Molecule (ICAM)-1 3.3 [ng/
mL], Interferon (IF)-γ [1.6 pg/mL], IL-1α [1.5 pg/mL], IL-
1β [2.2 pg/mL], IL-1Ra [156 pg/mL], IL-2 [5.9 pg/mL], IL-3
[1.6 pg/mL], IL-4 [9.4 pg/mL], IL-5 [2.7 pg/mL], IL-6
[1.6 pg/mL], IL-7 [8.2 pg/mL], IL-8/CXCL8 [1.3 pg/mL],
IL-10 [3.3 pg/mL], IL-12p40 [95 pg/mL], IL-12p70 [34 pg/
mL], IL-15 [0.19 ng/mL], IL-17 [1.6 pg/mL], IL-18
[6.7 pg/mL], IL-23 [0.66 ng/mL], Macrophage Inflam-
matory Protein (MIP)-1α/CCL3 [18 pg/mL], MIP-1β/
CCL4 [16 pg/mL], Matrix Metalloproteinase (MMP)-3
[26 pg/mL], MMP-9 [12 ng/mL], Monocyte Chemotactic
Protein (MCP)-1/CCL2 [27 pg/mL], SCF [65 pg/mL],
Tumor Necrosis Factor (TNF)-α [13 pg/mL], TNF-β
[3.0 pg/mL], and VEGF [20 pg/mL].
Concentrations of leptin were determined using
human leptin radioimmunoassay kits (Millipore) at the
Metabolism Core at the Nutrition Obesity Research
Center at the University of Alabama in Birmingham.
The LDD of the leptin assays was 0.97 ng/mL and the
inter-assay and intra-assay CVs were 4.18 % and 5.32 %,
respectively.
Data analyses
Survey data were collected from the Dooblo SurveyToGo
studio software and merged with the main database inde-
pendently by two investigators, and compared to ensure
accuracy. All data analyses were performed using SPSS
Statistics for Windows v21.0 (Armonk, NY: IBM Corp).
To examine serum inflammatory biomarker differ-
ences between GWI and HV, we tested group differences
in the levels of cytokines over time. Group differences in
cytokine concentrations were tested with generalized
estimating equations (GEE). GEEs properly account for
repeated measures within participants, and therefore allow
for more precise estimates of individual- and group-
means. GEEs were conducted in a univariate fashion. The
participant identification number was used as a subject
nesting variable, and the study day as the repeated mea-
sures index. Participant type (GWI or HV) was entered as
the between-subjects factor.
Differences in between-group cytokine variability
over the course of the immune monitoring period were
also tested. Day-to-day cytokine fluctuations were used
to calculate coefficients of variation (CVs) for each ana-
lyte, nested by individual. CV differences between the
GWI and HV groups were tested with independent
samples t-tests.
To test whether daily fatigue in GWI is related to fluc-
tuations in cytokines, we used linear mixed models
(LMM). LMMs can properly model effects with repeated
measures, as can GEEs, but can also allow for intercepts
and slopes to vary for each individual participant, by
treating the participant as a random factor. Fatigue and
cytokine data were person-centered (z-score-transformed)
and temporally smoothed using a three-day moving aver-
age to improve pattern detection [50, 51]. Because only
half of the HV individuals had measurable levels of fa-
tigue, these analyses were performed on the GWI individ-
uals only. For all applicable analyses, we determined
significance using an α = 0.05 false-discovery rate to adjust
for the 93 planned comparisons, yielding a p = 0.0098
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threshold significance. For the cytokine that was most sig-
nificantly associated with fatigue at the group-level, we
also performed visual analyses of the relationship between
each individual participant’s cytokine concentrations and
fatigue symptoms over time.
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